As of 2026-03-24, the EV/EBITDA ratio of Cytosorbents Corp (CTSO) is -4.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CTSO's latest enterprise value is 57.15 mil USD. CTSO's TTM EBITDA according to its financial statements is -12.86 mil USD. Dividing these 2 quantities gives us the above CTSO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.3x - 19.1x | 17.4x |
| Forward P/E multiples | 19.3x - 22.1x | 21.8x |
| Fair Price | (3.36) - (3.32) | (3.41) |
| Upside | -609.8% - -603.2% | -617.0% |
| Date | EV/EBITDA |
| 2026-03-18 | -4.38 |
| 2026-03-17 | -4.56 |
| 2026-03-16 | -4.38 |
| 2026-03-13 | -4.72 |
| 2026-03-12 | -4.83 |
| 2026-03-11 | -4.83 |
| 2026-03-10 | -5.16 |
| 2026-03-09 | -5.33 |
| 2026-03-06 | -5.26 |
| 2026-03-05 | -5.30 |
| 2026-03-04 | -5.21 |
| 2026-03-03 | -5.27 |
| 2026-03-02 | -4.97 |
| 2026-02-27 | -4.99 |
| 2026-02-26 | -4.84 |
| 2026-02-25 | -4.74 |
| 2026-02-24 | -4.62 |
| 2026-02-23 | -4.55 |
| 2026-02-20 | -4.33 |
| 2026-02-19 | -4.38 |
| 2026-02-18 | -4.38 |
| 2026-02-17 | -4.33 |
| 2026-02-13 | -4.33 |
| 2026-02-12 | -4.30 |
| 2026-02-11 | -4.21 |
| 2026-02-10 | -4.50 |
| 2026-02-09 | -4.51 |
| 2026-02-06 | -4.51 |
| 2026-02-05 | -4.27 |
| 2026-02-04 | -4.51 |
| 2026-02-03 | -4.59 |
| 2026-02-02 | -4.54 |
| 2026-01-30 | -4.27 |
| 2026-01-29 | -4.44 |
| 2026-01-28 | -4.58 |
| 2026-01-27 | -4.54 |
| 2026-01-26 | -4.44 |
| 2026-01-23 | -4.56 |
| 2026-01-22 | -4.54 |
| 2026-01-21 | -4.57 |
| 2026-01-20 | -4.55 |
| 2026-01-16 | -4.69 |
| 2026-01-15 | -4.62 |
| 2026-01-14 | -4.79 |
| 2026-01-13 | -4.86 |
| 2026-01-12 | -4.69 |
| 2026-01-09 | -4.51 |
| 2026-01-08 | -4.52 |
| 2026-01-07 | -4.56 |
| 2026-01-06 | -4.56 |